A plan for LEN access and new LEN resources! ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

View this email in your browser ([link removed])
[link removed] October 4, 2024


** A plan for LEN access and new LEN resources!
------------------------------------------------------------
Dear Advocate,

We learned of progress this week in building a sustainable market for choice in prevention with the news of generic licensing agreements for lenacapavir ([link removed]) as injectable PrEP. We are moving faster than the first decade of oral PrEP and the beginning rollout of injectable cabotegravir, which is an example of advocacy at its best, but making lenacapavir and new prevention options available to all who need it, requires even greater speed, scale and equity. Coordination and strategic actions among numerous and varied stakeholders are urgently needed, as outlined in this article from the New York Times ([link removed]) .

See AVAC’s updated Lens on LEN ([link removed]) , our new Plan for Accelerating Access to Injectable Lenacapavir for PrEP ([link removed]) , along with additional resources on LEN!
LEN resources

Plan


** From Clinical Trial Efficacy to Public Health Impact: A Plan for Accelerating Access to Injectable Lenacapavir for PrEP
------------------------------------------------------------

This plan provides a comprehensive view of all the moving parts and identifies priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered.
read the plan [link removed]
[link removed]
Advocates' Guide


** The Lens on LEN: The Basics on Injectable Lenacapavir as PrEP
------------------------------------------------------------

This updated advocates’ primer with the PURPOSE 2 data ([link removed]) provides background on lenacapavir and its trials, raises key questions, and explores next steps.
Read more [link removed]
[link removed]
podcast


** Lenacapavir: The case for investing in delivering HIV prevention

------------------------------------------------------------

This episode of PxPulse goes deep on LEN for PrEP. Recorded just days before Gilead’s announcement ([link removed]) that PURPOSE 2 also found very high efficacy, Dr. Flavia Kiweewa, a principal investigator of PURPOSE 1, the first trial to announce efficacy, lays out the research findings and what they mean. And Chilufya Kasanda Hampongo ([link removed]) of Zambia’s Treatment Advocacy and Literacy Campaign and Mitchell Warren ([link removed]) of AVAC talk about how to change a long history of squandered opportunities to get rollout right.
listen now [link removed]
[link removed]
webinar recording


** Breaking Ground: Expanding Access to Lenacapavir
------------------------------------------------------------

This webinar hosted by UNITAID brought together global health experts, community advocates, and civil society organizations to discuss the challenges and opportunities in ensuring equitable access to Lenacapavir.
view the recording [link removed]
infographic
[link removed]


** An Overview of Lenacapavir PrEP Trials
------------------------------------------------------------

The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1
Download the Graphic [link removed]
[link removed]
Article


** Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
------------------------------------------------------------

This news New York Times article raises key questions on access and pricing of lenacapavir. "Mr. Warren said he hoped the major global health agencies would work together to place orders large enough to have at least a million people on lenacapavir by the end of 2026, which would help send a clear signal to generics makers about the potential market for the product."
read more ([link removed])

Best,

AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423 [email protected] (mailto:[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])